NYSE:AGNAllergan Stock Price, Forecast & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

Allergan plc (NYSE:AGN) released its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $4.57 by $0.65. The firm earned $4.35 billion during the quarter, compared to analyst estimates of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. Allergan's revenue was up 6.6% compared to the same quarter last year. During the same period last year, the business posted $4.29 earnings per share. View Allergan's earnings history.

Allergan announced a quarterly dividend on Wednesday, March 18th. Stockholders of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of ∞. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

Allergan declared that its board has authorized a stock repurchase program on Tuesday, January 29th 2019, which permits the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its stock is undervalued.

10 equities research analysts have issued 1-year target prices for Allergan's shares. Their forecasts range from $165.00 to $203.00. On average, they expect Allergan's share price to reach $184.89 in the next twelve months. View analysts' price targets for Allergan.

News articles about AGN stock have been trending negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allergan earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Allergan.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan has a market capitalization of $0.00 and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

The official website for Allergan is www.allergan.com.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]